Search
forLearn
5 / 801 resultslearn ORPL
learn platycladus orientalis
learn Sodium PCA
learn zinc PCA
Research
5 / 1000+ resultsresearch Murine skin-derived multipotent papillary dermal fibroblast progenitors show germline potential in vitro
Mouse skin cells can become sperm-like cells in the lab.
research Skin-derived stem cells as a source of primordial germ cell- and oocyte-like cells
Skin-derived stem cells can become various cell types, including germ cell-like and oocyte-like cells.
research Low Intensity Ultrasound as an Antidote to Taxane/Paclitaxel-induced Cytotoxicity
Low intensity ultrasound may reduce side effects of chemotherapy drugs like paclitaxel.
research The role of 3Rs in the age of One Health: where we are and where we’re going
Innovative methods are reducing animal testing and improving biomedical research.
research PLCD1 and Pilar Cysts
The research linked PLCD1 gene variants to the development of trichilemmal cysts.
Community Join
5 / 1000+ resultscommunity Post Low-Level Laser Light Therapy Syndrome (PLLLTS )
Hair loss discussion includes LLLT treatments and a satirical condition called PLLLTS, causing patients to resemble lighthouses and attract moths. Some users express concern about others taking the satire seriously.
community cb-03-01 research chem (winlevi/clascoterone cream)
The user is considering using CB or clascoterone for hair loss, potentially as an alternative to RU. They're also contemplating asking a dermatologist for topical clascoterone cream to apply to their temple.
community Clascoterone - clearnet vendor
The conversation is about finding a clearnet vendor for clascoterone, also known as Winlevi, for hair loss treatment. The user is seeking recommendations via direct message.
community mallia therapeutics 8T3 scd83 molecule for ffa/lpp mainly and aga
A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.
community Pelage have presented only phase 2a. The rest of phase 2 for PP405 will be presented at a later medical meeting
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.